Jorge Hernando Cubero

5PUBLICATIONS
49CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Naturopathy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca

|Sep 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo

|Aug 14, 2025
External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy.

Paula Jimenez-Fonseca, Cristina Álvarez-Escola, Inmaculada Ballester Navarro

|Feb 24, 2025
Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry.

Alberto Carmona-Bayonas, Cristina Álvarez-Escolá, Inmaculada Ballester Navarro

|Jun 08, 2023
Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey.

Jorge Hernando, Teodora Kolarova, Chris Verslype

Pageof 1

Frequent Collaborators

4 joint publications

Paula Jimenez-Fonseca

3 joint publications

Teresa Alonso-Gordoa

3 joint publications

Carlos Lopez

2 joint publications

Enrique Grande